| Name | Title | Contact Details |
|---|---|---|
Sergey Tesler |
Executive Director, Global Regulatory Strategy, CMC | Profile |
Patrik Florencio |
SVP, Global Chief Compliance and Risk Officer | Profile |
Ellen Rosenberg |
Chief Legal Officer | Profile |
Heather Ramirez |
Executive Director - Lead Counsel US | Profile |
NEW Health provides high quality health care services for all residents within the communities we serve. We offer a sliding fee discount for health services to those who qualify. We believe that all people deserve...
Zogenix is a global pharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company has two late-stage development programs underway: FINTEPLA® (ZX008, fenfluramine oral solution) for the treatment of seizures associated with Dravet and Lennox-Gastaut syndromes, two rare and often-catastrophic childhood-onset epilepsies, and MT1621, a novel substrate enhancement therapy for the treatment of a rare genetic disorder called TK2 deficiency.
Afexa Life Sciences Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Sorenson Forensics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EIP Pharma is a private, clinical-stage therapeutics company focused on CNS disorders headquartered in Cambridge, Mass. EIP Pharma was launched in 2014 by R&D executives from the pharmaceutical and biotech industry who believed that emerging science supported exploring neflamapimod in Alzheimer’s disease.